Economic Evaluation of Donepezil Treatment for Alzheimer's Disease in Japan

Ikeda Shunya, Yamada Yukari, Ikegami Naoki

doi:10.1159/000048631

To demonstrate the economic impact of donepezil treatment for patients with mild-to-moderate Alzheimer's disease (AD) in Japanese clinical settings, we conducted a cost-effective analysis using the Markov model.<BR>This analysis was made from the societal view point, and the cost was estimated based on the fee schedule of the Japanese national health insurance and the entitled amount of the long-term care insurance. The results of the phase III clinical trial of donepezil on AD in Japan were used to estimate the drug efficacy. However, the epidemiological data on the natural history in the U. S. was used because they were unavailable in Japan. Based on the quality of life survey, quality-adjusted life years (QALYs) were calculated as an effectiveness measure.<BR>Under the base-case analysis with a 2-year time horizon, donepezil t r eatment for patients with mild-to-moderate AD was an economically dominant option compared to the conventional treatment; i. e. improved health outcomes and decreased costs. Further study will be needed when the data on the long-term effects of donepezil and the natural history data of AD patients become available.

Economic Evaluation of Donepezil Treatment for Alzheimer's Disease in Japan

Bibliographic Information

Search this article

Description

Journal

Citations (5)*help

Keywords

Details 詳細情報について

Export

Report a problem